Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
- PMID: 32360327
- PMCID: PMC7252084
- DOI: 10.1016/j.tmaid.2020.101710
Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
Conflict of interest statement
Declaration of competing interest Authors declare no competing interests.
Comment on
-
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.Travel Med Infect Dis. 2020 May-Jun;35:101647. doi: 10.1016/j.tmaid.2020.101647. Epub 2020 Apr 2. Travel Med Infect Dis. 2020. PMID: 32247927 Free PMC article. Review.
References
-
- “Solidarity” clinical trial for COVID-19 treatments n.d. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-r...
-
- Dose-finding study of favipiravir in the treatment of uncomplicated influenza - full text view - ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT01068912
-
- Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults - T705US316 - full text view - ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT02026349
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources